This story has been updated to clarify the current state of the Tissue of Origin test formerly of Pathwork Diagnostics, now owned and marketed by Response Genetics.

NEW YORK (GenomeWeb) — Modeling conducted by the Partnership for Health Analytic Research and funded by BioTheranostics has found that the company's CancerType ID test, a 92-gene assay to determine the origin of cancers of unknown primary site, is cost-effective and improves patient care.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.